A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Sickle Cell Disease Clinical Trial

Official title:

Pre-Transplant Immune Suppression With Hematopoietic Cell Transplantation From Haploidentical Donors for Adults and Children With Sickle Cell Disease or ß-Thalassemia (Haplo PTCy)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05736419
• Other study ID #: 23-009
• Status: Recruiting
• Phase: Phase 2
• Start date: February 9, 2023
• Est. completion date: February 9, 2026

Study information

• Verified date: May 2024
• Source: Memorial Sloan Kettering Cancer Center
• Contact: Maria Cancio, MD
• Phone: 212-639-2446
• Email: canciom[@]mskcc.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Hematopoietic Cell Transplantation/HCT involves receiving healthy blood-forming cells (stem cells) from a donor to replace the diseased or damaged cells in participants' bone marrow. The researchers think giving participants treatment with fludarabine and dexamethasone, drugs that lower the activity of the body's immune system (immune suppression), before standard conditioning therapy and HCT may help prevent serious side effects, including graft failure and GvHD. In this study, depending on how participants' body responds to the fludarabine and dexamethasone, the study doctor may decide participants should receive another drug, called cyclophosphamide, instead of fludarabine. In addition, depending on the results of participants' routine blood tests, participants may receive the drugs bortezomib and rituximab, which also help with immune suppression.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 24
• Est. completion date: February 9, 2026
• Est. primary completion date: February 9, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years to 50 Years

Eligibility

Inclusion Criteria:

• Age > 12 and < 35 years. Patients of age 2-12 and 35-50 years will be included after 8 patients reach day 100 without TRM and if = 4 of the first 8 patients reach day 100 without graft failure or grade III-IV acute GvHD.
• Suitable haploidentical donor.
• Performance score = 70% by Karnofsky Performance Scale or 0 to 1 by ECOG (age > 16 years), or Lansky Play-Performance Scale = 70% (age = 16 years).
• Adequate major organ system function as demonstrated by:
• For patients = 18 years of age:
• eGFR = 50 mL/min by Cockcroft-Gault formula
• For patients < 18 years of age:
• Serum creatinine clearance: glomerular filtration rate [GFR]) must be >50 mL/min/1.73 m2 as calculated by the Schwartz formula
• Conjugated (direct) bilirubin less than 2x upper limit of normal.
• ALT or AST = 3 times institutional upper limit of normal.
• Left ventricular ejection fraction = 50%.
• Diffusing capacity for carbon monoxide (DLCO) = 50% predicted, corrected for hemoglobin. For children < 7 years of age who are unable to perform PFT, oxygen saturation > 92% on room air by pulse oximetry.
• For SCD patients: HbSS, HbSC, HbS/ß° with one or more of the following complications:
• Acute chest syndrome: 2 or more episodes in the 2 years preceding enrollment
• Vaso-occlusive episodes: 3 or more episodes in the 2 years preceding enrollment
• Recurrent priapism: 2 or more episodes in the 2 years preceding enrollment
• History of osteomyelitis or osteonecrosis
• Cerebrovascular disease:
• Imaging evidence of prior overt or silent stroke
• History of a neurologic event resulting in focal neurologic deficits lasting > 24 hours
• Abnormal transcranial Doppler: Timed average maximum mean velocity = 200 cm/sec in terminal portion of the carotid or proximal portion of the middle cerebral artery or > 185 cm/sec plus evidence of intracranial vasculopathy if imaging TCD is used
• Pulmonary hypertension: Confirmed by right heart catheterization with mean pulmonary arterial pressure = 25 mmHg or mean pulmonary vascular resistance > 2 Wood units
• Red blood cell alloimmunization (> 3 alloantibodies)
• For thalassemia patients: Any genotype, with all of the following:
• Onset of red blood cell transfusion dependence during the first 3 years of life
• RBC transfusion history > 225 mL/kg/year or > 15 lifetime RBC transfusions
• Pre-transfusion hemoglobin = 7 g/dL
• Hepatosplenomegaly
• Patient or the patient's legal representative, parent(s) or guardian should be able to provide written informed consent. Assent of a minor if participant's age is at least seven and less than eighteen years.
• For sexually active men and women of childbearing potential, must agree to use a form of contraception considered effective and medically acceptable by the Investigator.

Exclusion Criteria:

• Prior myeloablative allogeneic HCT.
• Overt stroke or CNS instrumentation (e.g. for Moyamoya disease) within 6 months of enrollment.
• Liver cirrhosis. Mild fibrosis will be permitted, i.e. fine reticulin or grade 1 of 4, with bridging fibrosis.
• Hepatic iron content = 3 mg Fe/g liver dry weight
• HIV positive
• Active hepatitis B or C.
• Other uncontrolled infections.
• BMI > 40.
• Other malignancy/cancer diagnosis unless in remission after definitive therapy for a minimum of 2 years. Exceptions: Ductal carcinoma in situ, basal cell carcinoma, cervical intraepithelial neoplasia.
• Positive pregnancy test in a woman with child-bearing potential, defined as not post-menopausal for 12 months or no previous surgical sterilization.
• Inability to comply with medical therapy or follow-up.
• Known history of allergic reactions to any constituents of the cell product, including a known history of allergic reactions to DMSO.

Related Conditions & MeSH terms

• Anemia, Sickle Cell
• beta-Thalassemia
• Sickle Cell Disease
• Thalassemia
• Thalassemia, Beta

Intervention

Drug:
• Fludarabine
PK-guided fludarabine dosing will be used for each of the 2 cycles, using the InsightRx DoseMeRx platform.
• Cyclophosphamide
Cyclophosphamide will be administered Post-Transplant
• Tacrolimus
Tacrolimus will be administered beginning on day +5
• Mycophenolate Mofetil
Mycophenolate mofetil (MMF) will be administered three times daily starting on day +5.

Biological:
• Rabbit ATG
The dose and schedule of ATG will be determined according to the nomogram in Appendix A

Drug:
• Dexamethasone
Standard Regimen: Dexamethasone on days -68 to -64 and days -40 to -36.
• Bortezomib
Bortezomib on days -71, -68, -65, -61, -43, -40, -37, and -33
• Rituximab
Rituximab on days -71, -58, -43, and -30.

Locations

Country	Name	City	State
United States	Memorial Sloan Kettering at Basking Ridge (Consent only)	Basking Ridge	New Jersey
United States	Memorial Sloan Kettering Suffolk - Commack (Consent only)	Commack	New York
United States	Memorial Sloan Kettering Westchester (Consent only)	Harrison	New York
United States	Memorial Sloan Kettering Monmouth (Consent only)	Middletown	New Jersey
United States	Memorial Sloan Kettering Bergen (Consent only)	Montvale	New Jersey
United States	Memorial Sloan Kettering Nassau (All protocol activities)	Rockville Centre	New York

Sponsors (1)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with treatment related mortality/TRM or primary graft failure	The primary outcome is to estimate treatment-related mortality (TRM) or primary graft failure at 1 year post-HCT.	1 year

External Links

•   Memorial Sloan Kettering Cancer Center